MedTrace Logo

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

NCT00169208 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-08-28

No results posted yet for this study

Summary

This study is a multicentric trial evaluating the efficacy of the RFM regimen in patients aged 18 to 75 years with relapsed/refractory follicular non-Hodgkin's lymphoma (NHL).

Conditions

Interventions

DRUG

rituximab

375 mg/m² IV, D1 each cycle during 4 cycles

DRUG

fludarabine

40 mg/m²/day IV , D1 each cycle during 4 cycles

DRUG

mitoxantrone

10 mg/m² IV, D2-3-4 each cycle during 4 cycles

Sponsors & Collaborators

  • Lymphoma Study Association

    lead OTHER

Principal Investigators

  • Franck Morschhauser, MD · Lymphoma Study Association

  • Charles FOUSSARD, MD · French Innovative Leukemia Organisation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169208 on ClinicalTrials.gov